In contrast to findings with behavioral 20,21,22 and other pharmacological interventions 10,12,13 , the similar mean weight loss achieved with semaglutide 2.4 mg in STEP 5 at weeks 52 and 104 (15.6% and 15.2%, respectively) suggests that, on average, there is minimal weight regain over 104 weeks when once-weekly semaglutide therapy is continued
Tirzepatide is a dual agonist at both GIP and GLP-1 receptors
Consistent timing (typically morning before medications) gives the most interpretable trend
compounded tirzepatide pills Name-brand GLP-1s: not offered Bottom Line With competitive pricing and no long-term contracts, Henry Meds is an appealing choice for those seeking flexibility in GLP-1 care
However, such approaches often yield limited results, as they fail to address the underlying biological mechanisms driving weight gain
Think of it as suspended animation for the molecule